Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133923 | 1.00 | MEN1 (0.36) | MEN1KMT2AHRH3CYP2D6KCNH2 | |
| SCHEMBL22248553 | 0.87 | HRH3 (0.33) | HRH3CYP2D6KCNH2PDK1PDK2 | |
| SCHEMBL21867124 | 0.80 | HRH3 (0.36) | MEN1KMT2AHRH3CYP2D6KCNH2 | |
| SCHEMBL20528079 | 0.79 | USP2 (0.42) | MEN1KMT2AHRH3 | |
| SCHEMBL20523460 | 0.79 | USP2 (0.42) | MEN1KMT2AHRH3 | |
| SCHEMBL13676968 | 0.79 | USP2 (0.42) | MEN1KMT2AHRH3 | |
| SCHEMBL23312132 | 0.77 | SLC6A9 (0.31) | MEN1KMT2AHRH3EGLN1SLC6A9 | |
| SCHEMBL21666574 | 0.77 | CHRM1 (0.42) | MEN1KMT2APDK1PDK2PDK3 | |
| SCHEMBL23569900 | 0.76 | JAK3 (0.38) | — | |
| SCHEMBL23308415 | 0.76 | JAK3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | MEN1 4108/4885KMT2A 3173/4885HRH3 3975/4885 |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | MEN1 3998/4885KMT2A 3141/4885HRH3 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.